Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Calcium Signaling and Arrhythmia Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CALM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CALM1 WT & Clinical Mutants (N98S, D130G, F142L) High purity (>95%), Endotoxin Controlled. Sequence Verified. E. coli or HEK293 expressed. |
View CALM1 Products |
| Gene Delivery | CALM1 Promise-ORF / Lentivirus Full-length ORF (WT and pathogenic variants) for stable cell line construction. |
View CALM1 Products |
| Benchmark Ab | Anti-CALM1 Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and IHC. Sequence verified. |
View CALM1 Products |
| Validator | CALM1 siRNA Set Target-specific siRNA pool for knockdown verification in calcium flux assays. |
View CALM1 Products |
| Related Target A | CALM2 Highly homologous calmodulin isoform; essential for off-target selectivity and counter-screening. |
View CALM2 Products |
| Related Target B | CAMK2A Key downstream effector of CALM1; crucial for studying calcium/calmodulin-dependent kinase signaling. |
View CAMK2A Products |
| Related Target C | RYR2 Ryanodine Receptor 2; CALM1 modulates RYR2 to regulate cardiac calcium release. Target for CPVT therapeutics. |
View RYR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pathogenic Mutant Screening (LQTS/CPVT) | Sequence-verified mutant proteins (N98S, D130G, F142L) with precise theoretical MW matching. |
| Calcium-Dependent Conformational Shifts | High-purity, tag-free or small-tag recombinant CALM1 to prevent steric hindrance during SPR/ITC assays. |
| Isoform Cross-Reactivity (CALM1 vs CALM2/3) | Homolog protein panels strictly verified by mass spectrometry to ensure sequence identity. |
| Lack of Controls | Recombinant Benchmark Antibodies and sequence-validated positive controls included. |
| False Positives in Cell Assays | Sequence-verified siRNA pool included for target-specific knockdown validation. |
Live CALM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CALM1 (Calmodulin 1) is evolving along two distinct axes: addressing severe congenital cardiac channelopathies (such as Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia) caused by CALM1 mutations, and modulating calmodulin-dependent downstream pathways (e.g., CaMKII, Calcineurin) in oncology and neurodegeneration.
The race for CALM1 therapeutics is intensifying, with major players shifting focus from traditional non-selective small-molecule antagonists to peptide-based protein-protein interaction (PPI) inhibitors and gene therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting mutant-specific correction and precise downstream kinase modulation to minimize systemic toxicity associated with global calcium disruption.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / RNAi | Academic Medical Centers, Biotech Startups | LQTS, CPVT (Cardiac Arrhythmias) | Lentivirus for Stable Cell Line (Conformation-preserved cell-based calcium flux/electrophysiology) |
| Peptide Inhibitors (PPI) | Pharmaceutical Research Institutes | Oncology, Inflammatory Diseases | High-purity WT and Mutant Recombinant Proteins for SPR/ITC binding assays |
| Small Molecule Antagonists | Oncology & Neurology Therapeutics Developers | Glioblastoma, Alzheimer's Disease | Selectivity Assay (Need CALM1 vs CALM2/3 homolog panels to screen out off-target profiles) |